Ptc Therapeutics, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that develops treatments for rare diseases, with medicines including Sephience for PKU, Translarna and Emflaza for Duchenne muscular dystrophy, Evrysdi for spinal muscular atrophy, and the gene therapy Upstaza/Kebilidi. Founded in 1998 by RNA researcher Stuart Peltz, the company's name comes from "post-transcriptional control," the field of RNA biology it was built around.
3.00% Convertible Senior Notes due 2022
Sold 25.0K
Granted 25.0K · Sold 18.1K
Granted 19.1K · Sold 19.1K
Granted 17.6K · Sold 21.3K
Sold 10.8K
Granted 19.7K · Sold 19.7K
Granted 58.2K · Sold 114.2K
Granted 15.2K · Sold 21.5K
Granted 7.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schmertzler MichaelDirector · 5 transactions | — | 1.52M | — | — | 25.0K |
| Klein Matthew B.CHIEF EXECUTIVE OFFICER, Director · 8 transactions | +1.8% | 394.0K | 25.0K | — | 18.1K |
| Boulding Mark ElliottEXEC. VP AND CLO · 18 transactions | -0.5% | 107.1K | 19.1K | — | 19.1K |
| Pauwels EricCHIEF BUSINESS OFFICER · 3 transactions | +18% | 91.0K | 17.6K | — | 21.3K |
| Golden Lee ScottEVP & CHIEF MEDICAL OFFICER · 2 transactions | -12% | 79.1K | — | — | 10.8K |
| Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER · 2 transactions | 0% | 70.2K | 19.7K | — | 19.7K |
| Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · 23 transactions | -47.1% | 62.9K | 58.2K | — | 114.2K |
| Okey StephanieDirector · 5 transactions | -33.3% | 8.0K | 15.2K | — | 21.5K |
| Chutter Jessica CarolineDirector · 2 transactions | — | 7.3K | 7.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -249.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.